prof. Kris Gevaert (PhD)

CRIG member
Kris Gevaert

Senior full professor (Faculty of Medicine and Health Sciences, UGent)
Group leader (VIB-UGent Center for Medical Biotechnology)
Associate director (VIB-UGent Center for Medical Biotechnology)
Scientific advisor (Proteomics Expertise Center, VIB-UGent)


Research focus

As proteins are among the main molecular players in cells, their in-depth study is important for cancer research as in cancers, proteins are frequently deregulated or mutated. My group has introduced and applied novel technologies for comprehensive analysis and quantification of cellular proteins; the proteomes. We focus our proteome studies on the analysis of several protein modifications such as protein phosphorylation by kinases, protein ubiquitination and protein processing by proteases. In addition, we are particularly interested in N-terminal proteoforms that result from different usage of translation initiation codons amongst others. We use high-end mass spectrometers for identifying proteins with deregulated levels among different proteomes, allowing us to spot potential protein biomarkers. Classical and novel affinity purification-mass spectrometry (AP-MS) approaches are used to map the composition of protein complexes in which most, if not all, proteins reside and exert their functions. We master multiple reaction monitoring (MRM) approaches for quantifying proteins in samples, in which a mass spectrometer thus replaces a Western blot device. We are interested in protein biogenesis and combine ribo-seq data with positional proteomics data to map different N-terminal proteoforms and try to understand their functions. More recently, we implemented thermal proteome profiling proteomics for identifying the targets (and off-targets) of small molecule drugs and started clinical proteome studies in which we focus on disease-specific protein markers.

Research team

Key publications

  • 'Prune-1 drives polarization of tumor-associated macrophages (TAMs) within the lung metastatic niche in triple-negative breast cancer'. IScience, 2020. (PMID: 33426510)
  • 'An AKT2-specific nanobody that targets the hydrophobic motif induces cell cycle arrest, autophagy and loss of focal adhesions in MDA-MB-231 cells'. Biomed Pharmacother, 2020. (PMID: 33378961)
  • 'Integrator restrains paraspeckles assembly by promoting isoform switching of the lncRNA NEAT1'. Sci. Adv., 2020. (PMID: 32923585)
  • 'N-Terminal Proteoforms in Human Disease'. Trends Biochem Sci., 2020. (PMID: 32001092)
  • 'A Well-Controlled BioID Design for Endogenous Bait Proteins'. J. Proteome Res, 2019. (PMID: 30525648) 
  • 'Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination'. Science, 2018. (PMID: 30442762)
  • 'Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors'. Sci. Transl. Med, 2017. (PMID: 28615362) 
  • 'Trapping mammalian protein complexes in viral particles’. Nature Communication, 2016. (PMID: 27122307)
  • 'Melanoma addiction to the long non-coding RNA SAMMSON’. Nature, 2016. (PMID: 27008969)
  • 'Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors’. Journal of Medicinal Chemistry, 2015. (PMID: 25611072)
  • ‘The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma’. Molecular Cell, 2010. (PMID: 21145484)